Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK, SiranBio partner on oligonucleotide SA030 for cardiometabolic disease, $55M upfront, $1B milestones
Licensing deal, oligonucleotide, cardiometabolic, obesity, milestone payments, royalties - Read more

J&J MedTech's Ottava surgical robot meets primary endpoints in Ph1 gastric bypass clinical study
Medical device, metabolic, surgical robotics, obesity, bariatric surgery - Read more

MingMed Biotechnology's QA102 shows positive Ph2 results slowing intermediate dry age-related macular degeneration progression
Small molecule, ophthalmology, age-related macular degeneration, oral therapy, drusen volume, dry AMD - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Novo Nordisk's Wegovy pill hits 1M patients, generates $355M in Q1 sales, beating analyst expectations by 86%
Small molecule, metabolic disease, revenue impact, competitive - Read more

CellCentric raises $220M Series D to advance inobrodib for multiple myeloma
Oncology, small molecule, multiple myeloma, clinical-stage - Read more

Signadori Bio raises €11M ($12.9M) Seed round to advance solid tumour monocyte immunotherapy platform
Oncology, cell therapy, immuno-oncology, preclinical, solid tumors, platform technology - Read more

Avalo Therapeutics prices $375M public offering to advance abdakibart clinical development
Clinical-stage, autoimmune, antibody, IL-1β, inflammatory disease - Read more

Citius Oncology secures up to $36.5M in debt and equity to accelerate LYMPHIR commercialization
Oncology, small molecule, cutaneous T-cell lymphoma, clinical-stage - Read more

Kanvas Biosciences raises $48M Series A to advance gut microbiome immuno-oncology candidate
Oncology, microbiome, live biotherapeutic, immuno-oncology, AI/ML platform, preclinical - Read more

Brano Therapeutics raises $6.8M seed funding to advance heart failure treatments
Cardiovascular, small molecule, heart failure, preclinical - Read more

LTZ Therapeutics raises $38M to advance myeloid engager immunotherapy pipeline
Clinical-stage, oncology, autoimmune, immunotherapy, platform technology - Read more

Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing
Gene therapy, metabolic disease, major transaction, operational - Read more

Bayer to acquire Perfuse Therapeutics for up to $2.45B, bolstering eye disease drug pipeline
Small molecule, ophthalmology, major transaction, strategic - Read more

FDA launches AI-guided one-day inspection pilot to boost facility oversight efficiency
Manufacturing, operational, strategic, compliance - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Ipsen discontinues (ritivixibat) Ph2 trial in primary sclerosing cholangitis due to recruitment challenges
Small molecule, liver disease, IBAT inhibitor, primary sclerosing cholangitis, bile acid transporter - Read more

Bipartisan PRIMATE Act introduced to ban monkey imports for US research labs
Preclinical research, biosecurity, operational, regulatory - Read more

Novo Nordisk, Eli Lilly fined by French regulator for illegal indirect obesity drug promotion campaigns
GLP-1, obesity, regulatory, financial - Read more

FDA blocks publication of COVID and GSK Shingrix vaccine safety studies, citing unsupported conclusions
mRNA vaccine, infectious disease, regulatory, operational - Read more

BioCryst Pharmaceuticals scraps avoralstat eye candidate to refocus pipeline on rare diseases
Small molecule, rare disease, strategic, pipeline prioritization - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here